临床试验药物安全性 1506条(本栏目收费,不能显示细节,电话13136136841)
Cumulative toxicity basis of exclusion,94,96 96
Cyclophosphamide,329,602 602
Cyclosporin A,699,700 700
Cysteamine bitartrate,27 27
for nephropathic cystinosis,79 79
Conductance Regulator(CFTR),777 777
modulation of immune system,586 586
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4),603,605 605
Dasafinib for chronic myeloid leukemia,165,166 166
Committee (DSMC),500,501,561,562,720,727 727
Data manager,functions,530,532 532
Data Monitoring Committee (DMC),23,500,501,561,562,720 720
Dear Healthcare Professional letters,485,549,553 553
Decision aid informed consent,683,686 686
Decision tree Baselga schema,47 47
Katsumata schema,48,50 50
Decision-making process on adverse events that appear irrelevant to the study drug,541,542 542
dimethyl fumarate for multiple sclerosis,541 541
everolimus for preventing rejection of kidney transplants,542 542
AUC (area under the curve),23 23
Authority of FDA inspectors,720,721 721
maintenance therapy in,328,330 330
5-Aza-deoxycytidine myelodysplastic syndrome management,353 353